Recently, a regimen of frequent intravitreal injections of angiogenesis-inhibiting anti-VEGF reagents has proven to be a very successful treatment for age-related macular degeneration [7], [8] and shows promise for diabetic retinopathy [9]. This evidence concerns the gene VEGFA and age-related macular degeneration.